TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical ...
PharmaTher (PHRRF) has received an Amendment Acknowledgement Letter from the U.S. Food and Drug Administration for its New Drug Application for Ketamine. In the AAL, the FDA determined this is a ...
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical ...
(MENAFN- GlobeNewsWire - Nasdaq) The Assigned FDA Approval Goal Date is June 4, 2025 TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the“Company” or“PharmaTher ...
TORONTO, March 11, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the ...
Solving the shortage problem of Ketamine and unlocking its pharmaceutical potential Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM ...
TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback